February 5, 1987 |
In a new approach to fighting cancer, doctors say they have used ultraviolet light to activate a powerful drug in the bloodstream and apparently vaccinate cancer victims against their own disease. The technique, described in today's New England Journal of Medicine, has produced remarkable remissions in some people, suffering a relentlessly fatal form of blood cancer, who had not responded to ordinary treatment. The therapy - which was tested at Columbia-Presbyterian Medical Center in New York City and at the medical centers at the University of Pennsylvania, the University of California at San Francisco, the University of Vienna and the University of Dusseldorf - appears to marshal the body's own immune defenses to zero in on cancer and destroy it. It seems to do this without causing nausea, hair loss or any of the other common side-effects of chemotherapy or radiation.
December 26, 2011 |
Question: Can you explain acute myelogenous leukemia? Someone we know was recently diagnosed with it, and two weeks later he was dead. What makes it so deadly? Answer: Acute myelogenous leukemia, or AML, is a cancer of the blood in which immature, abnormal white blood cells grow rapidly and uncontrollably in the bone marrow and interfere with its ability to produce red blood cells, healthy white blood cells, and platelets. It's a fairly rare cancer, with men affected more often than women.
September 9, 2016 |
Merck & Co. said the Food and Drug Administration is reviewing its immunotherapy cancer drug Keytruda as a first-line treatment for patients with advanced lung cancer. The FDA has assigned "priority review" and designated it as a "breakthrough therapy" with a target action date of Dec. 24, the company said. Keytruda, a monoclonal antibody that works by increasing the ability of the body's immune system to help detect and fight tumor cells, is already approved as a second-line treatment for patients who have undergone chemotherapy for advanced non-small-cell lung cancer, and whose condition worsens.
May 23, 2016 |
One of the biggest challenges for the companies now racing to develop T-cell therapies for cancer is figuring out how to make personalized, living products on an assembly-line scale. Each patient's own T-cells - the soldiers of the immune system - must be siphoned from the blood, coaxed to multiply, genetically engineered to recognize and attack cancer cells, then returned to the patient. Now, Cellectis, a French biotechnology company partnering with Pfizer, says it has used gene-editing technology to achieve a major advance: a "universal" T-cell product, made with healthy donor cells and used "off-the-shelf.
September 8, 2012
Former U.S. Sen. Arlen Specter, who announced Aug. 28 that he was again battling cancer, was released Friday from the Hospital of the University of Pennsylvania, his family said. Specter, 82, was expected to return to the hospital periodically for additional treatment of non-Hodgkins lymphoma, a brief announcement said. Specter, who first was elected in 1980, has had repeated medical troubles, starting with a benign brain tumor diagnosed in 1993. He had radiation treatments in 1996 and a heart bypass operation in 1998.
March 20, 2016
The Leukemia & Lymphoma Society (LLS) drew more than 600 to its Red & White Ball at the Marriott Downtown Philadelphia on March 12. Supporters enjoyed an evening that included a silent auction, cocktails and hors d'oeuvres, dinner, and dancing, all for a great cause. LLS is the world's largest voluntary health agency dedicated to blood cancer. The mission of LLS is to support cancer research to seek treatments and cures for leukemia, lymphoma, Hodgkin's disease, and myeloma. The event brought in a record- breaking $570,000, bringing the total to $1.4 million raised over the last three years by the Red & White Ball.
July 10, 2016
On June 10, the Leukemia & Lymphoma Society (LLS) hosted its grand finale to its fund-raising competition with the announcement of the 2016 Man and Woman of the Year. The Eastern Pa. chapter of LLS, the world's largest voluntary health agency dedicated to finding cures for blood cancer, set a goal of raising $500,000 in the competition, which started March 29. About 400 attended the event at the Loews Philadelphia Hotel. The $384,000 in proceeds will go toward finding a cure for leukemia, lymphoma, Hodgkin's disease, and myeloma.
March 6, 2009 |
Scientists would receive $5.5 million to study a first-of-its-kind cancer cluster in Northeastern Pennsylvania under a provision inserted by Sen. Arlen Specter in the federal spending bill moving through Congress. The cluster is potentially linked to environmental hazards. Under the $410 billion federal spending bill moving through Congress, the Centers for Disease Control and Prevention would receive $5 million to study cases of polycythemia vera (PV), a rare blood cancer that turned up in unusually high numbers in an area 80 miles northwest of Philadelphia, said Specter (R., Pa.)
April 16, 2014 |
STATWISE, IT was the greatest day Adam DiMichele ever had. The former Temple quarterback, now the Owls' wide receivers coach, helped sign up 225 people for the "Be the Match" bone marrow registry yesterday. The program, operated by the National Marrow Donor Program (NMDP), helps find matches for those in need. According to the NMDP website, a person is diagnosed with a blood cancer every 4 minutes. And, every 10 minutes, someone dies from a blood cancer. Each year, thousands with blood cancers such as leukemia and lymphoma are cured.